Tandem Diabetes Care (TNDM) Competitors $12.43 +0.34 (+2.81%) Closing price 04:00 PM EasternExtended Trading$12.38 -0.05 (-0.39%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TNDM vs. LIVN, WRBY, INSP, LQDA, LMAT, PRCT, AORT, EYE, ENOV, and CNMDShould you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Tandem Diabetes Care vs. Its Competitors LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies LeMaitre Vascular PROCEPT BioRobotics Artivion National Vision Enovis CONMED Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Is TNDM or LIVN more profitable? LivaNova has a net margin of -16.13% compared to Tandem Diabetes Care's net margin of -20.51%. LivaNova's return on equity of 14.57% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Tandem Diabetes Care-20.51% -65.40% -13.87% LivaNova -16.13%14.57%6.91% Do institutionals & insiders hold more shares of TNDM or LIVN? 97.6% of LivaNova shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend TNDM or LIVN? Tandem Diabetes Care currently has a consensus target price of $22.44, suggesting a potential upside of 80.51%. LivaNova has a consensus target price of $59.71, suggesting a potential upside of 8.71%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tandem Diabetes Care 0 Sell rating(s) 11 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.31LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to TNDM or LIVN? In the previous week, Tandem Diabetes Care had 2 more articles in the media than LivaNova. MarketBeat recorded 13 mentions for Tandem Diabetes Care and 11 mentions for LivaNova. LivaNova's average media sentiment score of 1.36 beat Tandem Diabetes Care's score of 1.25 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, TNDM or LIVN? LivaNova has higher revenue and earnings than Tandem Diabetes Care. LivaNova is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTandem Diabetes Care$940.20M0.89-$96.03M-$3.09-4.02LivaNova$1.25B2.39$63.23M-$3.89-14.12 Which has more risk and volatility, TNDM or LIVN? Tandem Diabetes Care has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. SummaryLivaNova beats Tandem Diabetes Care on 11 of the 17 factors compared between the two stocks. Get Tandem Diabetes Care News Delivered to You Automatically Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNDM vs. The Competition Export to ExcelMetricTandem Diabetes CareMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$816.91M$6.74B$5.73B$10.31BDividend YieldN/A1.21%5.90%4.63%P/E Ratio-4.0218.5757.1222.76Price / Sales0.89194.74528.74123.58Price / CashN/A21.6137.1760.46Price / Book3.104.9412.796.29Net Income-$96.03M$176.38M$3.28B$270.51M7 Day Performance-1.04%4.79%0.22%2.15%1 Month Performance14.88%7.07%4.61%6.35%1 Year Performance-70.89%10.43%68.33%25.48% Tandem Diabetes Care Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNDMTandem Diabetes Care4.4573 of 5 stars$12.43+2.8%$22.44+80.5%-72.5%$816.91M$940.20M-4.022,650Positive NewsLIVNLivaNova3.0804 of 5 stars$58.32+0.6%$59.71+2.4%+14.2%$3.18B$1.25B-14.992,900Positive NewsWRBYWarby Parker1.5103 of 5 stars$26.74+2.8%$24.06-10.0%+80.0%$2.81B$771.32M-382.003,780Analyst UpgradeInsider TradeINSPInspire Medical Systems4.8955 of 5 stars$83.51-3.4%$164.50+97.0%-60.3%$2.47B$802.80M48.271,246Positive NewsLQDALiquidia Technologies3.6972 of 5 stars$27.98-3.0%$32.11+14.8%+173.3%$2.41B$14M-16.4650Positive NewsLMATLeMaitre Vascular3.1652 of 5 stars$97.07-0.4%$97.60+0.5%+3.0%$2.20B$219.86M47.12490Positive NewsPRCTPROCEPT BioRobotics3.1429 of 5 stars$38.92-4.3%$73.22+88.1%-53.2%$2.17B$274.95M-25.11430Positive NewsAnalyst ForecastAORTArtivion3.2325 of 5 stars$43.34-0.3%$40.63-6.2%+57.4%$2.04B$388.54M-103.191,600Positive NewsEYENational Vision2.6425 of 5 stars$23.08-1.7%$24.73+7.1%+117.0%$1.83B$1.82B-128.2213,411Positive NewsENOVEnovis4.0339 of 5 stars$31.39-2.3%$51.00+62.5%-25.4%$1.79B$2.11B-2.207,367Positive NewsCNMDCONMED4.2229 of 5 stars$53.78-2.2%$59.80+11.2%-31.3%$1.66B$1.31B15.233,900Insider Trade Related Companies and Tools Related Companies LIVN Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives LMAT Alternatives PRCT Alternatives AORT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNDM) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tandem Diabetes Care With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
